Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

BioTech 365

MARCH 2, 2021

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical License to Nobel prize winning CRISPR technology supports internal research and development DUBLIN, Ireland–(BUSINESS WIRE)–ERS Genomics Limited, which was formed … Continue reading (..)

Gene Editing 40

Gene Editing Genome Genomics Licensing 40

pharmaphorum

OCTOBER 8, 2020

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. The big biotech meanwhile has an antisense drug in trials for a subtype of inherited ALS, licensed from Ionis Pharma, in phase 3 clinical trials. Jennifer Doudna. Benjamin Oakes.

Gene Editing 69

Gene Editing Gene In-Vivo Clinical Trials 69

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. “The

Genome 52

Genome Genomics Licensing Licensing 52

BioTech 365

FEBRUARY 16, 2021

ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ZeClinics is applying CRISPR technology to create gene edited zebrafish disease models DUBLIN & BARCELONA, Spain–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide … Continue reading → (..)

Genome 40

Genome Genomics Licensing Licensing 40

BioTech 365

OCTOBER 13, 2020

Food analysis and biotechnology company licenses gene editing technology DUBLIN & KANAGAWA, Japan–(BUSINESS WIRE)–ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has … Continue (..)

Genomics 40

Genomics Genome Reagent Gene Editing 40

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40